Lantheus announces collaboration with a NIA-sponsored study called CLARiTT

Lantheus announced a collaboration agreement with a National Institute on Aging, NIA,-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging, CLARiTT. This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography imaging agent, in its investigation of Alzheimer’s disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. “MK-6240 is poised to play a pivotal role in propelling Alzheimer’s diagnosis and treatment research to new heights,” said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. “This agreement aligns with Lantheus’ purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies. In an era defined by an unprecedented number of Alzheimer’s diagnoses, the CLARiTI study represents a significant milestone in Alzheimer’s research, with the potential to change the trajectory of this degenerative disease.”